We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+12.56%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$401M
AUM Growth
+$10.4M
Cap. Flow
+$8.42M
Cap. Flow %
2.1%
Top 10 Hldgs %
79.05%
Holding
28
New
4
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$11.8M
2
CLDX icon
Celldex Therapeutics
CLDX
+$10.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$8.57M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.93M
5
VKTX icon
Viking Therapeutics
VKTX
+$4.92M

Top Sells

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$11.9M
2
KYNB
Kyntra Bio
KYNB
+$10.8M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.92M
4
PEAR
Pear Therapeutics, Inc. Class A Common Stock
PEAR
+$4.27M
5
IRON icon
Disc Medicine
IRON
+$3.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
26
IDEAYA Biosciences
IDYA
$3.44B
– –
-868,520
Closed -$11.9M
ISEE
27
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-284,626
Closed -$6.92M
PEAR
28
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
– –
-16,744,113
Closed -$4.27M
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q2 2023 Portfolio in Review

As of Q2 2023, 5AM Venture Management held 28 positions worth $401M, up 2.7% from $391M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

5AM Venture Management's Q2 2023 filing shows 4 new, 3 increased, 1 reduced and 4 closed positions. Its largest new stake was Zentalis Pharmaceuticals: 490,000 shares worth $13.8M. The largest sale was IDEAYA Biosciences, an estimated $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q2 2023 buy was Zentalis Pharmaceuticals: 490,000 shares worth $13.8M.
  • 5AM Venture Management added most to MoonLake Immunotherapeutics in Q2 2023, an estimated $8.57M increase.
  • 5AM Venture Management's biggest Q2 2023 reduction was Disc Medicine, cutting an estimated $3.55M.
  • 5AM Venture Management fully exited IDEAYA Biosciences in Q2 2023, selling an estimated $11.9M.
  • 5AM Venture Management's ten largest holdings make up 79% of its $401M portfolio in Q2 2023.
  • 5AM Venture Management opened 4 new positions and closed 4 in Q2 2023.
  • 5AM Venture Management's portfolio value rose 2.7% quarter-over-quarter to $401M.

Based on 5AM Venture Management's 13F filing for Q2 2023, filed 14 Aug 2023.